FDA backs Roche's Gazyva in first-line follicular lymphoma

ZURICH, Nov 16 (Reuters) - The U.S. Food and Drug Administration on Thursday expanded approvals for Roche's Gazyva to include previously untreated follicular lymphoma, bolstering the Swiss drugmaker's efforts to strengthen its portfolio of blood cancer medicines.